Biotricity is a medical technology company providing remote cardiac monitoring solutions. Biotricity develops wearable ECG patches and software for ambulatory cardiac monitoring, allowing physicians to track patient heart rhythms outside hospital settings. The Biocore Pro flagship product transmits ECG data in near real-time via cellular connectivity to a monitoring platform for physician review. Biotricity also offers the Bioflux device for high-acuity monitoring and the Biocore patch for Holter monitoring. Biotricity uses an insourcing model where the company provides technology to physician practices for a recurring fee. This allows physicians to bill insurers directly for diagnostic services rather than Biotricity acting as a third-party testing facility. Biotricity generates revenue primarily through flat-fee technology subscriptions, with additional income from usage-based fees. Biotricity expands by leveraging Group Purchasing Organization contracts to access hospital networks, conducting clinical pilot programs, and increasing Biotricity's presence across U.S. states. Biotricity also maintains a chronic care segment featuring a consumer heart monitor and a remote patient monitoring platform. Biotricity is developing AI-driven diagnostic tools to automate data analysis and improve operational efficiency.
Read full business overview →Mid to long-term bullish thesis
View →Mid to long-term bearish thesis
View →Mid to long-term bull-bear debate
View → NEWSummary and scoring of the bull-bear debate
View →Find ideas with similar bull or bear theses
View →Investor-relevant company attributes
View →Key risks to the business
View →Comparisons of annual risk disclosures
View →